China Pharma Holdings (CPHI) Asset Utilization Ratio (2011 - 2026)
China Pharma Holdings (CPHI) posted Asset Utilization Ratio of 0.1 for Q1 2026, down 40.8% on a QoQ basis from 0.18 in Q4 2025, and down 64.48% year-over-year from 0.3 in Q1 2025.
China Pharma Holdings (CPHI) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
China Pharma Holdings' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.1 for Q1 2026.
- Quarterly Asset Utilization Ratio fell 64.48% year-over-year to 0.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1 (down 64.48% YoY) and the FY2025 annual result came in at 0.18, down 37.47% from the prior year.
- Asset Utilization Ratio was 0.1 for Q1 2026 at China Pharma Holdings, down from 0.18 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.5 in Q3 2023 and bottomed at 0.1 in Q1 2026.
- A 5-year average of 0.37 and a median of 0.41 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio gained 18.36% — and 2026, when it slumped 64.48%.
- China Pharma Holdings' Asset Utilization Ratio stood at 0.48 in 2022, then decreased by 7.6% to 0.44 in 2023, then retreated by 27.5% to 0.32 in 2024, then slumped by 44.57% to 0.18 in 2025, then plunged by 40.8% to 0.1 in 2026.
- Business Quant data shows CPHI's Asset Utilization Ratio at 0.1 in Q1 2026, 0.18 in Q4 2025, and 0.27 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.18 |
| Sep 30, 2025 | 0.27 |
| Jun 30, 2025 | 0.31 |
| Mar 31, 2025 | 0.30 |
| Dec 31, 2024 | 0.32 |
| Sep 30, 2024 | 0.40 |
| Jun 30, 2024 | 0.41 |
| Mar 31, 2024 | 0.39 |
| Dec 31, 2023 | 0.44 |
| Sep 30, 2023 | 0.50 |
| Jun 30, 2023 | 0.48 |
| Mar 31, 2023 | 0.48 |
| Dec 31, 2022 | 0.48 |
| Sep 30, 2022 | 0.47 |
| Jun 30, 2022 | 0.42 |
| Mar 31, 2022 | 0.41 |
| Dec 31, 2021 | 0.47 |
| Sep 30, 2021 | 0.51 |
| Jun 30, 2021 | 0.51 |